BioCatalyst

Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib — catalyst calendar

1 verified catalyst event(s) referencing Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib, each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-10-29
in 3mo
ESTIMATED
 READOUT
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and
Phase 3 · Carcinoma, Renal Cell
 Merck Sharp & Dohme LLC Pembrolizumab, Belzutifan, Pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.